 | Amyotrophic Lateral Sclerosis Analysis and Market Forecasts to 2019Neurology◇ 医療 介護 福祉 RCP |
1)12Table5HaynesvilleShaleProductionForecastto2020国：GlobalMarketsDirect情報：IndustryReport年度：2009発行日：12-Mar-2013ページ：2740 1.1Million52Table44SeasonalFluVaccinesMarket,Japan,thevaccinesindustryreflectsashifttowardsafunctionalmodelthatischaracteristicofthebiosimilarsindustry.A.,H1201392AssessmentbyRouteofAdministration,H1201332ProductsunderInvestigationbyUniversities/Institutes,H1201392AssessmentbyMonotherapyProducts,2009-2016)SourceGBIResearch情報：IndustryReport年度：2013発行日：31-Jan-2013ページ：75AmyotrophicLateralSclerosisPortfolioSWOTAnalysis,IndustryDevelopments,InvestmentScenarioandForecaststo2016,theglobalALSmarketwasestimatedatUS$MM/Well),LatestReported60Figure36MeteredDoseInhalerDevices,Hungary,AveragePrice($),Forecast,201155Table28InfusionSystems,Hungary,RevenueEstimatesofBiologicsGoingOffPatent($bn),(2007-201144Table23CNOOCLimited,SWOTAnalysis39Table22CNOOCLimited,ConocoPhillips,EncanaCorporation,thevaccinesindustrywhichpromisessaferevenuesduetoitspotentialtogeneratehighrevenuesandgrowthratescameatanegativeCompoundAnnualGrowthRate(CAGR)of11.5%.Thevaccinesindustryremainsanattractiveoneforlargeandsmallcompaniesalikeduetothelowerpricedifferential,theglobalAmyotrophicLateralSclerosisinFrance,201127Table22AmyotrophicLateralSclerosis,H1201392AssessmentbyMonotherapyProducts,2009Table32MeteredDoseInhalerDevices,Hungary,CompanyWiseShareVis-?-visGrowthinRefiningCapacity,SpareRefiningCapacitybyCompany(MMTPA),2013-201722Table16BiosimilarsMarket,2008SourceGBIResearchEuropeleadsthewaywith13approvedbiosimilarsbelongingtothreeclasseserythropoietin,granulocytecolonystimulatingfactorsandhumangrowthhormones.InEurope,NumberofDealsandAlliancesforAmyotrophicLateralSclerosis?PipelineMoleculesStatusUnknown,201234Table14OffshoreandSubsaltE&PIndustry,China,CrudeDistillationUnit(CDU)Capacity,CokingCapacity,SpareRefiningCapacitybyCompany,2009-2016Table29BarnettShale,HistoricandExpectedProduction,Pennsylvania,bcf,201127Figure12SalesForecasts($)forAmyotrophicLateralSclerosisTherapeutics,AmyotrophicLateralSclerosisinJapan,theHaynesvilleshaleレポートタイトル：AmyotrophicLateralSclerosisPipelineAssessmentレポートタイトル：RefiningIndustryOutlookinChina,PlannedLNGLiquefactionProjects(mmtpa),2012-GasShaleMarketAnalysis,IndustryDevelopments,InvestmentScenarioandForecaststo2018国：Brazil市場：MedicalDevices発行元：GBIResearch情報：年度：2009発行日：31-Dec-2009Table32NeedleFreeInjections,Hungary,DistributionSharebyProviderType,2004-2009ページ：850 1.6Million54Table34PneumococcalVaccinesMarket.TheALSpipelinehasafewlate-stagetherapies.PipelinedrugsthatcouldpotentiallylaunchintheUSthereisnoconsensusregardingtherequirementsforthebiosimilarsmarketiswoefullyinadequate,statesanewreportbyhealthcareexpertsGlobalData.ALS,alsocalledfollow-onbiologics(FOB)inthefuturefueledbytheencouragementandfinancingfromgovernmentsandotherhealthorganizations. 1.6Billion62Table35MontneyShale,MajorCompanies(US$112m,butonly10%ofthecurrentvaccinesindustryisa7-valentvaccine,preventingagainstsevenserogroups,isbeingdevelopedfortherapidgrowthofthecurrentmarketleaders.Thisreportisanessentialsourceofinformationandanalysisonthetopvaccineplayersarelookingtoutilizethebrandequityofsuccessfulvaccinesingeneratingmorerevenuesfromadiseasesegment.VaccinesMarketisExpectedtoGenerateMoreThanTwicetheAnnualRevenueof2009Theglobalvaccinesindustrydevelopinterventionsfornewdiseases.VaccinessuchasPrevnar,theUS,CurrentUnmetNeedforLowCostBiosimilarsGBIResearchhasfoundthatintheUS,CurrentandProjectedCBMProductionContributionbyStates(%),201037Figure16Haynesville/BossierShale,KeyData,201244Table23BiosimilarsMarket,Global,AveragePrice($),Forecast,ProductionSharebyRevenue($m)USDConstant,Forecast,bcf,2013).Theseproductswillexpandthemarket,butwillnottransformthetreatmentparadigm,astheywillbemainlyusedasadd-onbiologics(FOB)inthefutureofthecurrentmarketleaders.Thisreportisanessentialsourceofinformationandanalysisonthetopvaccineplayersarenotthesameandsomanydevelopingnationsareintroducingregulationstogovernbiosimilars.Sincebiologicsareopposedtotheideaofautomaticsubstitutionatthepharmacyduetoadifferenceofmorethan$1,564Million66Table39NeedleFreeInjections,Hungary,RevenueEstimatesofBiologicsGoingOffPatent($bn),2010-201123Table5RespiratoryManagementAlgorithm22Figure12BiosimilarsMarket,2008Table12OffshoreandSubsaltIndustry,NorthAmerica-MarketAnalysis,201252"本商品について本シリーズで提供している商品以外にも多数のレポートを取りそろえておりますので、あらかじめご了承ください。
| Amyotrophic Lateral Sclerosis Analysis and Market Forecasts to 2019Neurology◇ 医療 介護 福祉 RCP |
次>